Navigation Links
NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director

HUBBARD, Ohio, April 8, 2008 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC Pink Sheets: NNLX) a nano-biotechnology company announces publication of 2007 financial data and a director appointment.

NanoLogix has posted 2007 unaudited financials. 2007 expenditures were reduced by 42% over 2006, while funding for 2007 Research and Development was increased by 19%. The information can be accessed at:

NanoLogix welcomes Bert Pharis to the Board of Directors. Mr. Pharis was formerly President and CEO of Sygnet Wireless, a Cellular Telephone Company in Northeastern Ohio and Western Pennsylvania, from the mid-Eighties until Sygnet's 1998 sale to Dobson Communications. Mr. Pharis then served as a Director of Dobson Communications, sitting on both the Audit and Compensation Committees, through the 2007 sale of Dobson to AT&T. He was President and CEO of Logix Communications, a Competitive Local Exchange Carrier operating primarily in Texas and Oklahoma, from 1999 through 2001. Following that he spent two years as President and CEO of Ortheon Medical, a Medical Device Company in Orlando, Florida.

Bret Barnhizer, CEO of NanoLogix stated, "Bert Pharis is a welcome addition to our new Board of Directors, bringing extensive corporate business expertise in addition to experience with the processes involved in obtaining FDA approval for medical devices."

About NanoLogix, Inc.

NanoLogix is a leading innovator in the research, development, and commercialization of nano-biotechnologies, applications and processes. The Company has 31 granted Patents and multiple Patents Pending for bioreactor- based Hydrogen Production, revolutionary rapid medical testing technologies, and bioremediation. Information on NanoLogix is available at .

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.


Investor Relations

Bret Barnhizer, CEO

Telephone: 330-534-0800


SOURCE NanoLogix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
2. National Public Radio (NPR) Features Broadcast Articles on NanoLogix Hydrogen Bioreactor Operation at Welchs Foods
3. NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program
4. NanoLogix, Inc. Makes Stock Pick List
5. NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update
6. NanoLogix Inc. to Present at EBW Expo & Conference 2007
7. NanoLogix Inc. Announces Historical First in Energy Generation With Bioreactor-Produced Hydrogen at Welchs
8. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
9. Olympus FluoroPoint(TM) System Provides High-Sensitivity Single Molecule and Protein Interaction Analysis for Screening and Research
10. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
11. SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
Post Your Comments:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
Breaking Biology News(10 mins):